Generate Biomedicines Uses AI to Create Proteins That Have Never Existed

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Generate Biomedicines today released a preprint describing a breakthrough in protein science that opens up the possibility of generating novel proteins with desired functional or other properties at will. This is made possible by their new machine learning (ML) model, Chroma, which Generate believes will herald a new era in which proteins – life’s most functional molecules – can become truly programmable, with a transformative impact on human health.

The work reaffirms that our planet’s immense biodiversity, encoded by protein sequences resulting from ~3.5 billion years of evolution, is just a drop in the bucket of all possible protein concepts. Generate has demonstrated how these concepts can now be accessed through their generative ML-based model, Chroma, and used at the service of a powerful method for designing novel proteins.

“We believe our model will have revolutionary implications. It’s like learning to “write” the mysterious language of proteins. Now that we have this capability, the possibilities of what we can produce are endless,” said Gevorg Grigoryan, Ph.D., co-founder and chief technology officer of Generate Biomedicines. “The transition from conventional drug discovery to generative biology will mean that we will no longer discover suboptimal drugs that nature designed for her own purposes; Instead, we will develop or manufacture specially designed, highly effective medicines.”

The ability to program proteins has promising and important implications for the development of novel therapeutics that will bring new drugs to patients faster, cheaper, and better tailored to their specific conditions. As Generate’s platform continually learns from each new protein it produces and validates in the lab, it will enable therapeutic development on an unprecedented scale.

Read the preprint and blog post to learn more about Chroma.

In the next step, the manuscript is submitted for review. The preprint describing Chroma has also been submitted to

About Generate Biomedicines

Generate Biomedicines is the first drug generation company to pioneer a machine learning-based multimodal generative biology platform capable of on-demand generation of new drugs across a broad range of biological modalities. The platform can dramatically improve the speed at which targets and therapeutics are identified and validated, the specificity of target binding by generated proteins, and the cost of identifying and developing clinical candidates. The company’s platform represents a potentially fundamental shift in what is possible in the field of therapeutic development, by addressing the key challenges in drug discovery and dramatically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of basic research in its Labs unit and launched in 2020. Learn more about Generate Biomedicines by visiting or by following the company Twitter and LinkedIn.

READ :  Faculty active in Dahlonega Science Cafe

Leave a Reply

Your email address will not be published. Required fields are marked *